MET改动,包括MET第14外显子跳跃变体,MET扩增,MET过表达,和MET融合,在原发性肿瘤发生和对靶向治疗的获得性抵抗中发挥关键作用,特别是EGFR酪氨酸激酶抑制剂。它们代表着重要的诊断,预后,和许多实体瘤类型的预测性生物标志物。然而,由于MET改变的复杂性和平台技术的多样性,MET改变的检测具有挑战性.因此,高灵敏度的技术,特异性,和可靠的分子检测精度需要克服这些障碍,并有助于生物标志物指导的治疗。当前的综述强调了MET改变在多种癌症中作为致癌驱动因素的作用,以及它们在靶向治疗抗性发展中的参与。此外,我们的审查提供了有关选择用于检测MET外显子14跳跃变体的各种跨平台技术的概述和建议,MET扩增,MET过表达,和MET融合。此外,讨论了这些常见检测平台背后的挑战和障碍。
MET alterations, including MET exon 14 skipping variants, MET amplification, MET overexpression, and MET fusion, play pivotal roles in primary tumorigenesis and acquired resistance to targeted therapies, especially EGFR tyrosine kinase inhibitors. They represent important diagnostic, prognostic, and predictive biomarkers in many solid tumor types. However, the detection of MET alterations is challenging due to the complexity of MET alterations and the diversity of platform technologies. Therefore, techniques with high sensitivity, specificity, and reliable molecular detection accuracy are needed to overcome such hindrances and aid in biomarker-guided therapies. The current
review emphasizes the role of MET alterations as oncogenic drivers in a variety of cancers and their involvement in the development of resistance to targeted therapies. Moreover, our
review provides an overview of and recommendations on the selection of various cross-platform technologies for the detection of MET exon 14 skipping variants, MET amplification, MET overexpression, and MET fusion. Furthermore, challenges and hurdles underlying these common detection platforms are discussed.